Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects
Arvinas’ cash burn and lack of pipeline candidates hurt its outlook. See why ARVN stock is a sell, despite a healthy cash ...
PMLive10h
Pfizer/Arvinas’ vepdegestrant shows promise in phase 3 breast cancer study
The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...
PharmExec6d
Phase III Trial Data Show Vepdegestrant Produces Encouraging Outcomes in ER+/HER2- Advanced or Metastatic Breast Cancer
Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and ...
Investing2d
Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook
The company is currently awaiting topline data from the Phase 3 VERITAC-2 trial, which is expected to be released in the first quarter of 2025. This trial is crucial for Arvinas, as it will ...
Olema Oncology price target lowered to $25 from $30 at Oppenheimer
Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Olema Oncology (OLMA) to $25 from $30 but keeps an Outperform rating on ...
MPR2d
Vepdegestrant Beneficial in ER+/HER2- Breast Cancer With ESR1 Mutations
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
Investing6d
Arvinas’s SWOT analysis: biotech stock faces pivotal trials amid competition
The company’s lead programs focus on breast cancer treatments, with the VERITAC-2 trial being a central piece of its clinical strategy. This Phase 3 trial, evaluating an oral Selective Estrogen ...
Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?
Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
Arvinas price target lowered to $12 from $48 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Arvinas (ARVN) to $12 from $48 and keeps an Equal Weight rating on the shares after the ...